NASH in nondiabetic endocrine disorders

Timothy Wang, Wei Yang, Siddika E Karakas, Souvik Sarkar

Research output: Contribution to journalReview article

Abstract

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease, including hepatic steatosis, inflammation, and fibrosis. NAFLD carries the risk of progression to cirrhosis with its associated complications and hepatocellular carcinoma. It is now the most common liver disease in the Western world and its prevalence is increasing. While the association between NAFLD and type 2 diabetes has been well documented, there is significantly less understanding of the pathophysiology and progression of NAFLD in patients with other endocrine disorders affecting metabolism in various ways. Some of the more common endocrine disorders such as polycystic ovarian syndrome, growth hormone deficiency, hypothyroidism, and hypogonadism are known in clinical practice to be associated with NAFLD. Medications that alter the endocrine system such as tamoxifen and adrenal steroids have also been attributed to significant NAFLD. The key to management of NAFLD at this time are dietary changes and exercise to achieve weight loss. Unfortunately, a large proportion of the patients with these endocrine disorders are unable to achieve either. This review aims to examine and summarize the current published literature that have evaluated the association between NAFLD and the above endocrine disorders and potential therapeutic interventions in each case.

Original languageEnglish (US)
Pages (from-to)315-320
Number of pages6
JournalMetabolic Syndrome and Related Disorders
Volume16
Issue number7
DOIs
StatePublished - Sep 1 2018

Fingerprint

Fibrosis
Western World
Endocrine System
Hypogonadism
Non-alcoholic Fatty Liver Disease
Polycystic Ovary Syndrome
Tamoxifen
Hypothyroidism
Type 2 Diabetes Mellitus
Growth Hormone
Liver Diseases
Weight Loss
Hepatocellular Carcinoma
Steroids
Exercise
Inflammation
Liver
Therapeutics

Keywords

  • endocrinopathies
  • hypogonadism
  • hypothyroidism
  • nonalcoholic fatty liver disease
  • nonalcoholic steatohepatitis
  • polycystic ovarian syndrome

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

NASH in nondiabetic endocrine disorders. / Wang, Timothy; Yang, Wei; Karakas, Siddika E; Sarkar, Souvik.

In: Metabolic Syndrome and Related Disorders, Vol. 16, No. 7, 01.09.2018, p. 315-320.

Research output: Contribution to journalReview article

@article{9c1a932f08194a2b91d02bdd6519378c,
title = "NASH in nondiabetic endocrine disorders",
abstract = "Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease, including hepatic steatosis, inflammation, and fibrosis. NAFLD carries the risk of progression to cirrhosis with its associated complications and hepatocellular carcinoma. It is now the most common liver disease in the Western world and its prevalence is increasing. While the association between NAFLD and type 2 diabetes has been well documented, there is significantly less understanding of the pathophysiology and progression of NAFLD in patients with other endocrine disorders affecting metabolism in various ways. Some of the more common endocrine disorders such as polycystic ovarian syndrome, growth hormone deficiency, hypothyroidism, and hypogonadism are known in clinical practice to be associated with NAFLD. Medications that alter the endocrine system such as tamoxifen and adrenal steroids have also been attributed to significant NAFLD. The key to management of NAFLD at this time are dietary changes and exercise to achieve weight loss. Unfortunately, a large proportion of the patients with these endocrine disorders are unable to achieve either. This review aims to examine and summarize the current published literature that have evaluated the association between NAFLD and the above endocrine disorders and potential therapeutic interventions in each case.",
keywords = "endocrinopathies, hypogonadism, hypothyroidism, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, polycystic ovarian syndrome",
author = "Timothy Wang and Wei Yang and Karakas, {Siddika E} and Souvik Sarkar",
year = "2018",
month = "9",
day = "1",
doi = "10.1089/met.2018.0044",
language = "English (US)",
volume = "16",
pages = "315--320",
journal = "Metabolic Syndrome and Related Disorders",
issn = "1540-4196",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - NASH in nondiabetic endocrine disorders

AU - Wang, Timothy

AU - Yang, Wei

AU - Karakas, Siddika E

AU - Sarkar, Souvik

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease, including hepatic steatosis, inflammation, and fibrosis. NAFLD carries the risk of progression to cirrhosis with its associated complications and hepatocellular carcinoma. It is now the most common liver disease in the Western world and its prevalence is increasing. While the association between NAFLD and type 2 diabetes has been well documented, there is significantly less understanding of the pathophysiology and progression of NAFLD in patients with other endocrine disorders affecting metabolism in various ways. Some of the more common endocrine disorders such as polycystic ovarian syndrome, growth hormone deficiency, hypothyroidism, and hypogonadism are known in clinical practice to be associated with NAFLD. Medications that alter the endocrine system such as tamoxifen and adrenal steroids have also been attributed to significant NAFLD. The key to management of NAFLD at this time are dietary changes and exercise to achieve weight loss. Unfortunately, a large proportion of the patients with these endocrine disorders are unable to achieve either. This review aims to examine and summarize the current published literature that have evaluated the association between NAFLD and the above endocrine disorders and potential therapeutic interventions in each case.

AB - Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease, including hepatic steatosis, inflammation, and fibrosis. NAFLD carries the risk of progression to cirrhosis with its associated complications and hepatocellular carcinoma. It is now the most common liver disease in the Western world and its prevalence is increasing. While the association between NAFLD and type 2 diabetes has been well documented, there is significantly less understanding of the pathophysiology and progression of NAFLD in patients with other endocrine disorders affecting metabolism in various ways. Some of the more common endocrine disorders such as polycystic ovarian syndrome, growth hormone deficiency, hypothyroidism, and hypogonadism are known in clinical practice to be associated with NAFLD. Medications that alter the endocrine system such as tamoxifen and adrenal steroids have also been attributed to significant NAFLD. The key to management of NAFLD at this time are dietary changes and exercise to achieve weight loss. Unfortunately, a large proportion of the patients with these endocrine disorders are unable to achieve either. This review aims to examine and summarize the current published literature that have evaluated the association between NAFLD and the above endocrine disorders and potential therapeutic interventions in each case.

KW - endocrinopathies

KW - hypogonadism

KW - hypothyroidism

KW - nonalcoholic fatty liver disease

KW - nonalcoholic steatohepatitis

KW - polycystic ovarian syndrome

UR - http://www.scopus.com/inward/record.url?scp=85052933260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052933260&partnerID=8YFLogxK

U2 - 10.1089/met.2018.0044

DO - 10.1089/met.2018.0044

M3 - Review article

C2 - 29873585

AN - SCOPUS:85052933260

VL - 16

SP - 315

EP - 320

JO - Metabolic Syndrome and Related Disorders

JF - Metabolic Syndrome and Related Disorders

SN - 1540-4196

IS - 7

ER -